Comparison of Direct Negative Chronotropic and Positive Inotropic Effects of Sematilide to Those of E-4031 and MS-551 and the Reverse Frequency-Dependent Prolongation of Cardiac Refractoriness of Sematilide

Journal of Cardiovascular Pharmacology

Volumn 27, Issue 1, 1996, Pages 159-166

  Yamada, Akio ^a   Motomura, Shigeru ^b   Hashimoto, Keitaro ^a  

^a UNIVERSITY OF YAMANASHI   (Japan)

^b HIROSAKI UNIVERSITY   (Japan)

Author keywords

Class III antiarrhythmic drug; Dependent effect; Negative chronotropic effect; Positive inotropic effect; Reverse frequency; Sema tilide

Indexed keywords

1 [2 (6 METHYL 2 PYRIDYL)ETHYL] 4 (4 METHYLSULFONYLAMINOBENZOYL)PIPERIDINE; NIFEKALANT; SEMATILIDE;

ANIMAL TISSUE; ARTICLE; ATRIOVENTRICULAR CONDUCTION; CHRONOTROPISM; DOG; DRUG EFFECT; HEART ARRHYTHMIA; HEART MUSCLE REFRACTORY PERIOD; INOTROPISM; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTI-ARRHYTHMIA AGENTS; ATRIOVENTRICULAR NODE; DOGS; FEMALE; HEART RATE; MALE; PAPILLARY MUSCLES; PIPERIDINES; PROCAINAMIDE; PYRIDINES; PYRIMIDINONES; SINOATRIAL NODE;

EID: 0030068405     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199601000-00025     Document Type: Article

References (30)

1. The Cardiac Arrhythmia Suppression Trial Investigators. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 1989;321:406-12.
2. Burkart F, Phisterer M, Kiowski W, Follath F, Burkhardt D. Effect of antiarrhythmic therapy on mortality in survivors of myocardial infarction with asymptomatic complex ventricular arrhythmias: Basal Antiarrhythmic Study of Infarct Survival (BASIS). J Am Coll Cardiol 1990;16:1771-8.
3. Cairns JA, Connolly SJ, Gent M, Roberts R. Postmyocardial infarction mortality in patients with ventricular premature depolarizations: Canadian amiodarone myocardial infarction arrhythmia trial pilot study. Circulation 1991; 84:550-7.
4. Ceremuzynski Y, Kleczar E, Krzeminska-Pakula M, et al. Effect of amiodarone on mortality after myocardial infarction: a double-blind, placebo-controlled, pilot study. J Am Coll Cardiol 1992;20:1056-62.
5. Courtney KR. Interval-dependent effects of small antiarrhythmic drugs on excitability of guinea pig myocardium. J Mol Cell Cardiol 1989;12:1273-86.
6. Hondeghem LM, Snyders DJ. Class III antiarrhythmic agents have a lot of potential but a long way to go: reduced effectiveness and dangers of reverse use dependence. Circulation 1990;81:686-90.
7. k blocking drugs. UK-68,798 (dofetilide) and E-4031. Cardiovasc Res 1993;27:861-7.
8. Lumma WC. Rational design of sematilide as class 111 antiarrhythmic agents. J Med Chem 1987;30:755-8.
9. Argentieri TM, Carrol MS. Electrophysiologic mechanism of action of the class II antiarrhythmic agents sematilide and clofilium. J Mol Cell Cardiol 1990;22(suppl III):81.
10. + current: differential sensitivity to block by class III antiarrhythmic agents. J Gen Physiol 1990; 96:195-215.
11. Nakaya H, Tohse N, Takeda Y, Kanno M. Effects of MS-551, a new class III antiarrhythmic drug, on action potential and membrane currents in rabbit ventricular myocytes. Br J Pharmacol 1993;109:157-63.
12. Motomura S, Wu ZJ, Hashimoto K, Lacidipine, a new long-acting dihydropyridine calcium antagonist, has high vascular selectivity against all intracardiac variables. Heart Vessels 1993;8:16-22.
13. Greenberg SS, Luisi A, Long JP, Williamson HE. Pharmacology of sematilide, a non-quaternary class III antiarrhythmic agent. Drug Dev Res 1992;25:283-302.
14. Funck-Brentano C, Silberstein DJ, Roden DM, Wood AJ, Woosley R. A mechanism of D-(+)-sotalol effects on heart rate not related to beta-adrenoceptor antagonism. Br J Clin Pharmacol 1990;30:195-202.
15. Argentieri TM. Sematilide. Cardiovasc Drug Rev 1992;10: 182-98.
16. Wang Z, Fermini B, Nattel S. Delayed rectifier outward current and repolarization in human atrial myocytes. Circ Res 1993:73:276-85.
17. Tseng GN, Huffman BF. Two components of transient outward current in canine ventricular myocytes. Circ Res 1989; 64:633-47.
18. Sager PT, Uppal P, Follmer C, Antimisiaris M, Pruitt C, Singh BN. Frequency-dependent electrophysiologic effects of amiodarone in humans. Circulation 1993,88:1063-71.
19. Wang J, Bourne GW, Wang Z, Villemaire C, Talajic M, Nattel S. Comparative mechanisms of antiarrhythmic drug action in experimental atrial fibrillation. Importance of use-dependent effects on refractoriness. Circulation 1993;88: 1030-44.
20. Sager PT, Nademanee K, Antimisiaris M, et al. Antiarrhythmic effects of selective prolongation of refractoriness; electro-physiologic actions of sematilide HCl in humans. Circulation 1993;88:1072-82.
21. Wong W, Pavlou HN, Birgersdotter UM, Holleman DE, Mohiuddin SM, Roden DM. Pharmacology of the class III antiarrhythmic agent sematilide in patients with arrhythmias. Am J Cardiol 1992;69:206-12.
22. Attwell D, Cohen I, Eisner DA. The effects of heart rate on the action potential of guinea-pig and human ventricular muscle. J Physiol (Lond) 1981;313:439-61.
23. Colatsky TJ, Follmer CH, Starmer CF. Channel specificity in antiarrhythmic drug action; mechanism of potassium channel block and its role in suppressing and aggravating cardiac arrhythmias. Circulation 1990;82:2235-42.
24. Wettwer E, Grundke M, Ravens U. Differential effects of the new class III antiarrhythmic agents almokalant, E-4031, and D-sotalol, and quinidine, on delayed rectifier currents in guinea pig ventricular myocytes. Cardiovasc Res 1992;26: 1145-52.
25. + current by dofetilide. Circ Res 1993;72:75-83.17.
26. McCleskey EW, Fox AP, Feldman D, Tsien RW. Different types of calcium channels. J Exp Biol 1986;124:177-90.
27. Honerjagar P. Cardioactive substances that prolong the open state sodium channels. Physiol Biochem Pharmacol 1982;92: 2-80.
28. Inoue M, Inoue D, Ishibashi K, et al. Effects of E-4031 on atrial fibrillation threshold in guinea pig atria: comparative study with class I antiarrhythmic drugs. J Cardiovasc Pharmacol 1994;24:534-4.
29. Reiter MJ, Mann DE, Reiffei JE, Hahn E, Hartz V. Significance and incidence of concordance of drug efficacy predictions by Holter monitoring and electrophysiological study in the ESVEM Trial. Electrophysiologic Study Versus Electrocardiographic Monitoring. Circulation 1995;91:1988-95.
30. Waldo AL, Camm AJ, deRuyter H, et al. Survival with oral d-sotalol in patients with left ventricular dysfunction after myocardial infarction: rationale, design, and methods (the SWORD trial). Am J Cardiol 1995;75:1023-7.